Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms' Tumor 1 Peptide Vaccination

Tatsuya Suwabe, Yasuhiko Shibasaki, Suguru Tamura, Takayuki Katagiri, Kyoko Fuse, Takashi Ushiki, Hirohito Sone, Miwako Narita, Masayoshi Masuko

Blood (2021) 138 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2021-146856

Published: 2021

Journal Articles

Genetic Manipulation Resulting in Decreased Donor Chondroitin sulfate Synthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model.

Suguru Tamura, MD, Takashi Ushiki, MD PhD, Tatsuya Suwabe, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD, Kyoko Fuse, MD PhD, Yasuhiko Shibasaki, MD PhD, Miwako Narita, MD PhD, Michihiro Igarashi, MDPhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137448

Published: 2020

Journal Articles

Distinct Effects of Chondroitin Sulfate on Hematopoietic Cells and the Stromal Microenvironment in Bone Marrow Hematopoiesis

Takayuki Katagiri, MD, Takashi Ushiki, MD PhD, Asami Kawasaki, PhD, Shun Uemura, MD, Tatsuya Suwabe, MD, Tomoyuki Tanaka, MD PhD, Kyoko Fuse, MD, Yasuhiko Shibasaki, MD, Hirohito Sone, MD PhD, Michihiro Igarashi, MD PhD, Masayoshi Masuko, MD PhD

Blood (2018) 132 (Supplement 1): 3852.

https://doi.org/10.1182/blood-2018-99-115796

Published: 2018

Journal Articles

Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

Kyoko Fuse, MD, Tomoyuki Tanaka, MD PhD, Shun Uemura, MD, Tatsuya Suwabe, MD, Takayuki Katagiri, MD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Tastuo Furukawa, MD PhD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2018) 132 (Supplement 1): 5260.

https://doi.org/10.1182/blood-2018-99-113251

Published: 2018

Journal Articles

Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

Tatsuya Suwabe, MD, Kyoko Fuse, MD, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD PhD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2018) 132 (Supplement 1): 5712.

https://doi.org/10.1182/blood-2018-99-115844

Published: 2018

Journal Articles

Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

Kyoko Fuse, MD, Shun Uemura, MD, Tatsuya Suwabe, MD, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD PhD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Tastuo Furukawa, MD PhD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2017) 130 (Supplement 1): 2044.

https://doi.org/10.1182/blood.V130.Suppl_1.2044.2044

Published: 2017

Journal Articles

Further Prognostic Factors for Stratification of Patients in the High-Risk HCT-CI Group Undergoing Allogeneic HCT

Yasuhiko Shibasaki, MD PhD, Tatsuya Suwabe, MD, Shun Uemura, MD, Takayuki Katagiri, MD, Tomoyuki Tanaka, MD, Takashi Ushiki, MD PhD, Kyoko Fuse, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2017) 130 (Supplement 1): 4590.

https://doi.org/10.1182/blood.V130.Suppl_1.4590.4590

Published: 2017

Journal Articles

Elucidation of Tumor-Promoting Effects of Novel Adherent Immature Myeloid Cells in Tumor

Takuya Tsubaki, MEng, Tetsuya Kadonosono, PhD, Tadashi Shiozawa, BEng, Takahiro Kuchimaru, PhD, Takashi Ushiki, MD PhD, Masayoshi Masuko, MD PhD, Shinae Kizaka-Kondoh, PhD

Blood (2016) 128 (22): 3690.

https://doi.org/10.1182/blood.V128.22.3690.3690

Published: 2016

Journal Articles

Evaluation of Liver Iron Deposition in Transfusion-Dependent Patients By Dual-Energy CT

Hironori Kobayashi, MD PhD, Norihiko Yoshimura, MD PhD, Takayuki Katagiri, MD, Takashi Ushiki, MD PhD, Kyoko Fuse, MD, Yasuhiko Shibasaki, MD PhD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD

Blood (2016) 128 (22): 3619.

https://doi.org/10.1182/blood.V128.22.3619.3619

Published: 2016

Journal Articles

The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

Kyoko Fuse, MD, Takayuki Katagiri, MD, Yasuhiko Shibasaki, MD PhD, Tomoyuki Tanaka, MD, Miwako Narita, MD PhD, Hirohito Sone, MD PhD, Masayoshi Masuko, MD PhD, Tatsuo Furukawa, MD PhD, Naoko Sato, MD PhD, Toshio Yano, MD PhD, Takashi Kuroha, MD PhD, Shigeo Hashimoto, MD PhD, Takashi Ushiki, MD PhD

Blood (2016) 128 (22): 2297.

https://doi.org/10.1182/blood.V128.22.2297.2297

Published: 2016

Journal Articles

Combination of Low Rate of γδ T Cells and High Rate of Regulatory T Cells after Allogeneic Stem Cell Transplantation Is a Poor Prognostic Factor for Patients with Hematological Neoplasm

Yasuhiko Shibasaki, MD, Syukuko Miyakoshi, MD, Takayuki Katagiri, MD, Kyoko Fuse, MD, Hironori Kobayashi, MD, Takashi Ushiki, MD, Masato Moriyama, MD, Jun Takizawa, MD, Miwako Narita, MD, Hirohito Sone, MD, Masayoshi Masuko, MD

Blood (2015) 126 (23): 5463.

https://doi.org/10.1182/blood.V126.23.5463.5463

Published: 2015

Journal Articles

Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual- Energy CT

Hironori Kobayashi, MD PhD, Norihiko Yoshimura, MD PhD, Takashi Ushiki, MD PhD, Yasuhiko Shibasaki, MD PhD, Masato Moriyama, MD PhD, Jun Takizawa, MD, PhD, Miwako Narita, MD PhD, Hirohito Sone, MDPhD, Masayoshi Masuko, MD PhD

Blood (2014) 124 (21): 2677.

https://doi.org/10.1182/blood.V124.21.2677.2677

Published: 2014

Journal Articles

Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy

Yasuhiko Shibasaki, MD PhD, Yoshinobu Seki, MD PhD, Tomoyuki Tanaka, MD, Syukuko Miyakoshi, MD, Kyoko Fuse, MD, Takashi Kozakai, MD, Hironori Kobayashi, MD PhD, Takashi Ushiki, MD PhD, Takashi Abe, MD PhD, Toshio Yano, MD PhD, Masato Moriyama, MD PhD, Takashi Kuroha, MD PhD, Noriatsu Isahai, MD PhD, Jun Takizawa, MD, PhD, Miwako Narita, MD PhD, Satoru Koyama, MD PhD, Tatsuo Furukawa, MD PhD, Hirohito Sone, MDPhD, Masayoshi Masuko, MD PhD

Blood (2014) 124 (21): 2334.

https://doi.org/10.1182/blood.V124.21.2334.2334

Published: 2014

Journal Articles

Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients

Masayoshi Masuko, MD, PhD, Tatsuo Furukawa, MD, PhD, Tadashi Koike, MD, Kazue Takai, MD, Koichi Nagai, MD, Kenji Kishi, MD, PhD, Yoshinobu Seki, MD, Hoyu Takahashi, MD, PhD, Sadao Aoki, MD, PhD, Takashi Kozakai, MD, Yasuhiko Shibasaki, MD, Takashi Ushiki, MD, Ken Toba, MD, PhD, Miwako Narita, MD, PhD, Masuhiro Takahashi, MD, PhD, Hirohito Sone, MD, PhD, Akira Shibata, MD

Blood (2013) 122 (21): 2744.

https://doi.org/10.1182/blood.V122.21.2744.2744

Published: 2013

Journal Articles

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Ruriko Tanaka, MMSc, Matthew S Squires, PhD, Shinya Kimura, MD, PhD, Asumi Yokota, MMSc, Kirsty Mallett, PhD, Tomoko Smyth, PhD, Neil T Thompson, PhD, Rina Nagao, Takahiro Yamauchi, MD, Takashi Ushiki, MD, John F Lyons, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 1104.

https://doi.org/10.1182/blood.V112.11.1104.1104

Published: 2008

Journal Articles

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Miki Takeuchi, MD, Shinya Kimura, MD, PhD, Junya Kuroda, MD, PhD, Takashi Ushiki, MD, Makoto Kawatani, PhD, Hiroyuki Osada, PhD, Kazuo Umezawa, PhD, Eiko Yasui, PhD, Masaya Imoto, PhD, Takashi Tsuruo, MD, PhD, Keiko Hodohara, MD, PhD, Tatsutoshi Nakahata, MD, PhD, Yoshihide Fujiyama, MD, PhD, Taira Maekawa, MD, PhD

Blood (2008) 112 (11): 3185.

https://doi.org/10.1182/blood.V112.11.3185.3185

Published: 2008

NARROW

The Diversity of Long-Term Persistent WT1-Specific Cytotoxic T Lymphocytes after Wilms' Tumor 1 Peptide Vaccination

Genetic Manipulation Resulting in Decreased Donor Chondroitin sulfate Synthesis Mitigates Gvhd Following Allogeneic Hematopoietic Cell Transplantation in a Murine Model.

Distinct Effects of Chondroitin Sulfate on Hematopoietic Cells and the Stromal Microenvironment in Bone Marrow Hematopoiesis

Marker Chromosomes Are a New Cytogenetic Adverse Risk Factor in AML after Allo-HCT

Clinical Features and Risk Factors of Post-Engraftment Bloodstream Infection in Allogeneic HCT

Patient-Based Prediction Algorithm of Relapse after Allo-HSCT for Acute Leukemia Using Machine Learning Approach

Further Prognostic Factors for Stratification of Patients in the High-Risk HCT-CI Group Undergoing Allogeneic HCT

Elucidation of Tumor-Promoting Effects of Novel Adherent Immature Myeloid Cells in Tumor

Evaluation of Liver Iron Deposition in Transfusion-Dependent Patients By Dual-Energy CT

The Predictive Factors of Favorable Prognosis after Allo-HSCT for Refractory Acute Leukemia

Combination of Low Rate of γδ T Cells and High Rate of Regulatory T Cells after Allogeneic Stem Cell Transplantation Is a Poor Prognostic Factor for Patients with Hematological Neoplasm

Imaging of Body Iron Stores in Transfusion-Dependent Patients By Liver Dual- Energy CT

Log Reduction Levels of WT1 mRNA Expression in BM after Chemotherapies Are Predictive Markers of Good Prognosis in AML Patients Achieved CR after Induction Therapy

Early Responses At 3 Months and 12 Months After Starting Imatinib As Predictive Factors For The Achievement Of Deep MR In Japanese CML Patients

Activity of the Multi-Targeted Kinase Inhibitor, AT9283 on Imatinib-Resistant CML Models.

Glyoxalase-I Inhibition Eliminates Hypoxia-Adapted CML Cells Resistant to Imatinib, Dasatinib, and INNO-406

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only